PF-Atlas › Weekly Digest › Week 42, 2026

Four New Trials Open, Inhaled Treprostinil Debated in NEJM, and Our Solver Hits 133 Combinations

October 5 to 12, 2026 · Active week

Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.

The week in plain words

Four new clinical trials opened this week, including a Phase 3 trial for a drug targeting IPF-related chronic cough and two Phase 2 trials testing new experimental compounds. The New England Journal of Medicine published a cluster of letters debating inhaled treprostinil, a drug already in the FDA filing pipeline. Meanwhile, our own PF-Atlas computer engine ran 133 drug combination simulations and flagged several interesting cross-disease ideas borrowed from spinal cord injury research. Nothing this week changes the core reality: IPF has no cure, and approved treatments can slow the disease but cannot undo scarring.

Where things stand now

Two drugs anchor the current standard of care: nintedanib and pirfenidone, both approved for years. Nerandomilast (brand name Jascayd) joined them in October 2025 as a third FDA-approved option. It works by blocking a protein called PDE4B, which damps down inflammation and the activation of scar-forming cells called fibroblasts. Inhaled treprostinil has completed Phase 3 and an FDA filing was submitted in 2026, but it is not yet approved. Admilparant is still in Phase 3 trials. All of these slow the disease. None reverse existing lung scarring, which is scar tissue that permanently replaces healthy lung.

The best option right now

For someone with IPF right now, the honest answer is that three FDA-approved drugs exist: nintedanib, pirfenidone, and the newest, nerandomilast. Each slows the rate at which the lungs scar, which matters enormously, but none can undo damage already done. Inhaled treprostinil looks promising based on Phase 3 data and is under FDA review, but it is not approved yet. Any treatment decision must be made with a specialist who knows the individual patient. There is no single best drug for everyone, and no option available today stops or reverses the disease.

How close are we to regeneration

Regenerating lung tissue, meaning actually regrowing healthy air sacs to replace scar tissue, remains a research goal, not an available treatment. The most advanced experimental ideas in our data are still preclinical, meaning they have only been tested in lab animals or cells, not in people. These include uPAR-CAR-T therapy, which uses engineered immune cells to clear out old dysfunctional cells called senescent cells, and a combination approach that would first clear those same senescent cells and then try to stimulate remaining stem cells in the lung to regrow. Both are experimental and unproven in humans. Regeneration is where researchers want to go, but no one is there yet.

Study of the week

This week's standout paper, published in the journal Tissue and Cell by Liang, Zhou, and colleagues in 2026, tested a creative delivery idea in mice. They took tiny bubble-like packages called exosomes from stem cells found in human umbilical cord tissue, loaded with small molecular passengers called tsRNAs (tiny fragments that can dial gene activity up or down), and delivered them as a mist that mice breathed in. In a mouse model of lung fibrosis, this appeared to reduce scarring. This is early-stage animal research, not a human trial. It is interesting because it explores whether stem cell signals, rather than the stem cells themselves, can be packaged and inhaled. That would be far simpler than transplanting living cells. But the distance from a mouse experiment to a proven human therapy is very large, and this remains purely experimental.

What changed since last week

Four trials that did not exist last week are now open. NCT07869147 is a Phase 2 trial of a new experimental drug called ORJ-001 specifically for IPF. NCT07868419 is a Phase 3 trial of nalbuphine extended-release tablets to reduce the severe chronic cough that makes daily life very hard for many IPF patients. NCT07862634 is a Phase 2 trial of AGMB-447, not yet enrolling but registered. NCT07867730 is a study of breathing muscle training for patients on mechanical ventilation with restrictive lung disease, which is the category IPF falls into. No previously listed trials changed status this week.

Our own search for a cure this week

PF-Atlas runs its own discovery engine every day. This is not a summary of other people's research. We built a genetic-algorithm solver, meaning a computer program that mimics evolution to find strong solutions, and we point it at combinations of existing, already-approved or already-studied drugs, including drugs originally designed for completely different diseases. The goal is to find cocktails that, in simulation, attack IPF from multiple angles at once. This week the solver evaluated 133 combination simulations and separately generated 106 cross-disease idea transfers and 2 formal hypotheses. These are computer-generated hypotheses only. They are not treatments, not clinical evidence, and not proven to work in humans. They are starting points for scientists to investigate further. The top-scoring formula our solver produced this week combined five agents: a WNT pathway activator called wnt_rspo3, an ECM remodeling inhibitor targeting the physical scaffold of scar tissue, an advanced HOPX activator to support healthy lung cell identity, a curcumin formulation targeting two inflammation pathways called TLR4 and NLRP3, and a miR-34a inhibitor to block a molecular signal that drives cell aging and scarring. The solver gave this combination a simulated lung function score of 100. That number is a model output, not a clinical result. The solver also flagged five new candidate agents this week, including a lung-targeted CAR agonist and several approaches aimed at a protein called TFCP2L1 that may help reprogram lung cells toward a healthier state. On the cross-disease side, our engine pulled 106 ideas from spinal cord injury research, centering on an enzyme called ChABC that in spinal cord work helps break down scar tissue, and asked whether an inhaled or airway-delivered form could do something similar in the lung, possibly combined with stem cells or immune-shifting therapies. Again, these are machine-generated hypotheses. We flag them because we think transparency about our process matters. You deserve to know when an idea comes from our own software rather than from a published trial.

Inside the PF-Atlas lab

Strongest simulated combination so far
WNT/RSPO3 agonist + ECM remodeling inhibitor + HOPX activator + Curcumin (TLR4/NLRP3) + miR-34a inhibitor
In our 24-month computer simulation this cocktail of already-known drugs moved lung function (FVC) toward about 99%. A model result and a research hypothesis, not a treatment.
New candidate ideas the solver found
  • CAR (Constitutive Androstane Receptor) Agonist, Lung Targeted
  • TP63 Phosphorylation Inhibitor (SCP1 analog)
  • SP-C Repressor with TFCP2L1 Activator and miR-122 Antagonist (Inhaled)
  • TFCP2L1 Transcriptional Reprogrammer (Inhaled)
  • TFCP2L1 Lung-Targeted Activator
Borrowed from other diseases (drug repurposing)
  • Spinal Cord Injury → IPF: Recombinant ChABC (enzymatic scar remodeling) + mesenchymal stem cell or alveolar progenitor co-transplantation to restore epithelial-mesenchymal communication
  • Spinal cord injury → IPF: Inhaled or intra-tracheal ChABC (or engineered variants with improved stability/half-life) combined with simultaneous macrophage polarization therapy (IL-4/IL-13 receptor antagonists like dupilumab or fesomersen) to shift pro-fibrotic M2 macrophages toward anti-fibrotic M1 phenotype
  • Spinal Cord Injury → IPF: ChABC (Chondroitinase ABC) engineered with improved half-life + bone marrow-derived mesenchymal stem cells (BMSCs) expressing anti-fibrotic factors (BMP7, HGF) delivered via inhalation or minimally invasive intrapulmonary injection
  • Spinal Cord Injury → IPF: Intratracheal delivery of ChABC (engineered for lung stability) combined with mesenchymal stem cells secreting anti-fibrotic cytokines (IL-10, TGF-β inhibitors). Phase 1 trials launching 2025 for SCI; pulmonary adaptation would involve nebulized or bronchoscopic administration.
  • Spinal cord injury → IPF: Intratracheal or nebulized recombinant ChABC (being developed for SCI in Phase 1/2 trials) adapted as a direct ECM-remodeling agent combined with anti-TGF-β checkpoint inhibitors
Hypotheses the model tested
  • If we combine pirfenidone + curcumin_tlr4_nlrp3 + nmn_nad, then chronic smoke-in
  • If we combine nerve regeneration support (KGF + FGF10) with senolytic clearance

Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.

Print this to show your pulmonologist →

Sources this week

New / updated trials
New studies
  • Research on the role and mechanism of SLC7A5 in idiopathic pulmonary fibrosis. · Molecular medicine reports 2026 PMID 42825353 on PubMed ↗
  • Serial multidomain six-minute walk assessment for dynamic risk prediction in idiopathic pulmonary fibrosis. · American journal of respiratory and critical care medicine 2026 PMID 42860051 on PubMed ↗
  • "Interstitial lung disease with associated severe pulmonary hypertension is rarely idiopathic by clinical or pathologic measures". · The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2026 PMID 42858771 on PubMed ↗
  • Inhalation therapies in interstitial lung diseases. · Expert opinion on drug delivery 2026 PMID 42858239 on PubMed ↗
  • Toward molecular endotypes of CLAD: dancing around the truth hidden in the tissue. · The European respiratory journal 2026 PMID 42855186 on PubMed ↗
  • Effects of combination metformin and nintedanib therapy in a mouse model of irradiation-induced pulmonary fibrosis. · Journal of radiation research 2026 PMID 42502979 on PubMed ↗
  • [Treatment of pulmonary fibrosis: Beginning of a new era]. · Pneumologie (Stuttgart, Germany) 2026 PMID 42849504 on PubMed ↗
  • Disrupting BRD4-BD1-p62 engagement restores protective autophagy. · Cell chemical biology 2026 PMID 42849434 on PubMed ↗
  • Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Reply. · The New England journal of medicine 2026 PMID 42842914 on PubMed ↗
  • Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. · The New England journal of medicine 2026 PMID 42842913 on PubMed ↗
  • Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. · The New England journal of medicine 2026 PMID 42842912 on PubMed ↗
  • Prevalence and patterns of inhalational exposures in patients with interstitial lung diseases: a cross-sectional study. · Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2026 PMID 42845091 on PubMed ↗
  • Predictive Model for Identifying Fibrotic Interstitial Lung Abnormalities on Computed Tomography for Respiratory Specialists. · Respirology (Carlton, Vic.) 2026 PMID 42844158 on PubMed ↗
  • Use of lung ultrasound surface wave elastography in patients with interstitial lung disease. · BMJ open respiratory research 2026 PMID 42843929 on PubMed ↗
  • Inhibition of the MER tyrosine kinase ameliorates pulmonary fibrosis by suppressing macrophage M2 polarisation and osteopontin signalling. · British journal of pharmacology 2026 PMID 42836432 on PubMed ↗
  • Almost There: Approaching a Pragmatic Definition of Combined Pulmonary Fibrosis and Emphysema. · Respirology (Carlton, Vic.) 2026 PMID 42836277 on PubMed ↗
  • Nebulized inhalation of exosomes from human umbilical cord mesenchymal stem cells alleviates bleomycin-induced pulmonary fibrosis through tsRNA cargos. · Tissue & cell 2026 PMID 42837852 on PubMed ↗
  • Integrative multiomics and machine learning identify uridine as a candidate modulator of MMP7-mediated immune cell infiltration in pulmonary fibrosis. · Journal of advanced research 2026 PMID 42833599 on PubMed ↗
  • Robust spectral averaging and chemical shift calculation for hyperpolarized (129)Xe MR spectroscopy. · Magnetic resonance imaging 2026 PMID 42833557 on PubMed ↗
  • Aging in a Dish: Pulmonary Organoids as Models of Lung Aging. · American journal of respiratory cell and molecular biology 2026 PMID 42832275 on PubMed ↗
Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.
Medical disclaimer. This digest summarizes public clinical-trial and research data in plain language for information only. It is not medical advice, a treatment recommendation, or a promise of any outcome. Evidence changes; treatments described as investigational are not proven cures. Always verify with ClinicalTrials.gov, PubMed and a qualified pulmonologist before any decision.